Sign In
Buy ABBV
$224.93
+7.86 (+3.62%)
At Close: Jun 04, 2026
Dividend Stocks With Strong Q4 Seasonality
01:20pm, Wednesday, 02'nd Oct 2024
Entering October is the strongest period of the year for three-month returns, and shorter-term returns are also some of the best. Here we take a look at 30 dividend stocks in the S&P 500 that have bee
AbbVie: $200 Peak (Rating Downgrade)
10:25am, Wednesday, 02'nd Oct 2024
AbbVie has transitioned beyond Humira's exclusivity loss, with strong growth from Skyrizi and Rinvoq, targeting $27 billion in sales by 2027. The stock has surged to $200, now trading at 16x 2025 EPS
AbbVie's Skyrizi And Rinvoq Deserve The Premium Growth Valuation
09:15am, Wednesday, 02'nd Oct 2024
AbbVie's high-growth investment thesis is undeniable indeed, despite Humira's painful patent expiry and the erosion observed in its sales thus far. Our optimism arises from Skyrizi's/Rinvoq's promisin
Available Nationwide: JUVÉDERM® VOLUMA® XC for Moderate to Severe Temple Hollowing
08:00am, Wednesday, 02'nd Oct 2024
JUVÉDERM® VOLUMA® XC is the One and Only Hyaluronic Acid Dermal Filler Indicated to Treat Cheeks, Chin, and Now Moderate to Severe Temple Hollowing1,2 Only Allergan Aesthetics, the Makers of BOTOX
5 Best Dividend Growth Stocks to Buy in October
07:30am, Wednesday, 02'nd Oct 2024
These five stocks are known for their generous dividend programs and robust business models.
Should You Buy AbbVie Stock After Recent Parkinson's Study Success?
04:00pm, Tuesday, 01'st Oct 2024
Investors who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth next year.
EU withdraws marketing authorisation for Abbvie's hepatitis C drug
12:03pm, Tuesday, 01'st Oct 2024
The European Medicines Agency said on Tuesday that it has withdrawn the marketing authorisation for Abbvie's hepatitis C drug Exviera at the request of the company.
AbbVie to Host Third-Quarter 2024 Earnings Conference Call
08:00am, Tuesday, 01'st Oct 2024
NORTH CHICAGO, Ill. , Oct. 1, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its third-quarter 2024 financial results on Wednesday, October 30, 2024, before the market opens.
AbbVie stock analysis: Rinvoq and Skyrizi are big catalysts
05:24am, Tuesday, 01'st Oct 2024
AbbVie (ABBV) stock price has done well this year as it surged to a record high of $200. It has jumped by more than 32% this year, outperforming the S&P 500 and Nasdaq 100 indices.
AbbVie Seeks Approval for Lung Cancer Candidate Teliso-V
12:16pm, Monday, 30'th Sep 2024
ABBV submits a BLA for Teliso-V to the FDA for treating previously treated non-small cell lung cancer patients with c-Met overexpression.
Wall Street Analysts Think AbbVie (ABBV) Is a Good Investment: Is It?
10:35am, Monday, 30'th Sep 2024
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employe
15 Best Dividend Stocks for Lifelong Passive Income
06:15am, Monday, 30'th Sep 2024
Dividend sustainability trumps high yields when selecting stocks for passive income. The featured companies span diverse sectors including healthcare, consumer goods, retail, finance, and real estate.
ABBV's Newly Added Parkinson's Disease Drug Meets Second Study Goal
02:41pm, Friday, 27'th Sep 2024
Data from a late-stage study shows that AbbVie's tavapadon reduced the burden of Parkinson's disease. The drug previously demonstrated efficacy as adjunctive therapy.
Final Trades: Meta, Accenture, Abbvie and Disney
01:23pm, Friday, 27'th Sep 2024
The Investment Committee give you their top stocks to watch for the second half.
- Teliso-V is an investigational antibody-drug conjugate (ADC) for patients with previously treated nonsquamous non-small cell lung cancer (NSCLC) with c-Met protein overexpression. - Biologics Licens
